- Tytuł:
- A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors
- Autorzy:
- Źródło:
- In JTO Clinical and Research Reports February 2024 5(2)
Czasopismo naukowe